CYP2D6 and CYP2C19 genotyping in psychiatry: bridging the gap between practice and lab

Anne (Bregje) Koopmans

Research output: ThesisDoctoral ThesisExternal prepared

175 Downloads (Pure)

Abstract

CYP2D6 and CYP2C19 are liver enzymes that play an important role in the breakdown of psychopharmaceuticals. The number of active alleles in the DNA determines how quickly these enzymes work and is translated into a phenotype. This phenotype can vary greatly per person and per ethnicity. There is a relationship between the speed of the enzyme and the occurrence of medication side effects. This study has mapped the prevalence of the different phenotypes worldwide. It has also been investigated whether there are fewer side effects in patients taking antipsychotics if you adjust the dosage of medication to the phenotype.
Original languageEnglish
Awarding Institution
  • Maastricht University
Supervisors/Advisors
  • van Harten, Pieter, Supervisor
  • Hoek, H.W., Supervisor, External person
  • Vinkers, D.J., Co-Supervisor, External person
Award date12 May 2021
Place of PublicationMaastricht
Publisher
DOIs
Publication statusPublished - 2021

Keywords

  • CYP2D6
  • CYP2C19
  • pharmacogenetics
  • genotyping
  • clinical practice

Cite this